Keymed Biosciences Inc.

SEHK:2162 Stock Report

Market Cap: HK$11.6b

Keymed Biosciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bo Chen

Chief executive officer

CN¥5.0m

Total compensation

CEO salary percentage98.5%
CEO tenure4.1yrs
CEO ownershipn/a
Management average tenure4.1yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

Market Participants Recognise Keymed Biosciences Inc.'s (HKG:2162) Revenues Pushing Shares 31% Higher

Apr 06
Market Participants Recognise Keymed Biosciences Inc.'s (HKG:2162) Revenues Pushing Shares 31% Higher

Growth Investors: Industry Analysts Just Upgraded Their Keymed Biosciences Inc. (HKG:2162) Revenue Forecasts By 11%

Mar 31
Growth Investors: Industry Analysts Just Upgraded Their Keymed Biosciences Inc. (HKG:2162) Revenue Forecasts By 11%

Keymed Biosciences Inc. (HKG:2162) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 28
Keymed Biosciences Inc. (HKG:2162) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?

Oct 21
Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?

There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump

May 13
There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump

News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat

Apr 03
News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat

Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 31
Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates

A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)

Nov 13
A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)

Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts

Sep 03
Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts

Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher

Mar 21
Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher

Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth

Jun 27
Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth

CEO Compensation Analysis

How has Bo Chen's remuneration changed compared to Keymed Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024CN¥5mCN¥5m

-CN¥515m

Sep 30 2024n/an/a

-CN¥629m

Jun 30 2024n/an/a

-CN¥743m

Mar 31 2024n/an/a

-CN¥551m

Dec 31 2023CN¥5mCN¥5m

-CN¥359m

Sep 30 2023n/an/a

-CN¥313m

Jun 30 2023n/an/a

-CN¥267m

Mar 31 2023n/an/a

-CN¥287m

Dec 31 2022CN¥4mCN¥4m

-CN¥308m

Sep 30 2022n/an/a

-CN¥281m

Jun 30 2022n/an/a

-CN¥253m

Mar 31 2022n/an/a

-CN¥2b

Dec 31 2021CN¥4mCN¥4m

-CN¥4b

Sep 30 2021n/an/a

-CN¥4b

Jun 30 2021n/an/a

-CN¥4b

Mar 31 2021n/an/a

-CN¥3b

Dec 31 2020CN¥231kCN¥227k

-CN¥819m

Dec 31 2019CN¥188kCN¥183k

-CN¥168m

Compensation vs Market: Bo's total compensation ($USD687.53K) is above average for companies of similar size in the Hong Kong market ($USD502.82K).

Compensation vs Earnings: Bo's compensation has increased whilst the company is unprofitable.

CEO

Bo Chen (49 yo)

4.1yrs

Tenure

CN¥4,976,000

Compensation

Dr. Bo Chen has been executive Director, chairman of Board and chief executive officer at Keymed Biosciences Inc. since April 03, 2021 and served as Director since April 23, 2018 until April 03, 2021. Dr....

Leadership Team

NamePositionTenureCompensationOwnership
Bo Chen
Executive Chairman & CEO4.1yrsCN¥4.98mno data
Gang Xu
Senior VP & Executive Director4.1yrsCN¥1.73mno data
Changyun Wang
Senior VP & Executive Director4.1yrsCN¥2.96mno data
Yanrong Zhang
CFO, VP & Joint Company Secretary4.7yrsno datano data
Qian Jia
Senior Vice President7.2yrsno datano data
Pak Yu Tam
Joint Company Secretary3.2yrsno datano data

4.1yrs

Average Tenure

49yo

Average Age

Experienced Management: 2162's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bo Chen
Executive Chairman & CEO7.1yrsCN¥4.98mno data
Gang Xu
Senior VP & Executive Director6.9yrsCN¥1.73mno data
Changyun Wang
Senior VP & Executive Director4.2yrsCN¥2.96mno data
Cheuk Kin Law
Independent Non Executive Director4.1yrsCN¥572.00kno data
Yang Ke
Independent Non Executive Director4.1yrsCN¥476.00kno data
Qi Chen
Non Executive Director6.9yrsno datano data
Xiao-Fan Wang
Independent Non-Executive Director4.1yrsCN¥476.00kno data
Yilun Liu
Non Executive Director4.2yrsno datano data
Min Chuan Wang
Non Executive Director4.2yrsno datano data

4.2yrs

Average Tenure

49yo

Average Age

Experienced Board: 2162's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/08 02:15
End of Day Share Price 2025/05/08 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Keymed Biosciences Inc. is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Wangbin ZhouChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited